UOC
TERN

UBS O'Connor’s Terns Pharmaceuticals TERN Stock Holding History

UBS O'Connor’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-273,619
Closed -$1.02M – 437
2025
Q2 		$1.02M Sell
273,619
-62,525
-19% -$195K 0.03% 215
2025
Q1 		$928K Buy
336,144
+195,844
+140% +$800K 0.02% 191
2024
Q4 		$777K Buy
140,300
+92,300
+192% +$625K 0.02% 252
2024
Q3 		$400K Buy
+48,000
New +$395K 0.01% 357

Other funds holding TERN

SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

UBS O'Connor's TERN Position: Q3 2025 in Review

UBS O'Connor sold out of Terns Pharmaceuticals (TERN) in Q3 2025, closing a stake of 273,619 shares — an estimated $1.02M sold.

UBS O'Connor first reported a position in TERN in Q3 2024 and held it in 4 quarters. The position peaked at $1.02M in Q2 2025. 141 funds tracked by Wall St. Rank hold TERN as of Q3 2025.

  • UBS O'Connor reported no remaining Terns Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 273,619 Terns Pharmaceuticals shares in Q3 2025, an estimated $1.02M.
  • UBS O'Connor first reported a position in Terns Pharmaceuticals in Q3 2024 and held it in 4 quarters.
  • UBS O'Connor's Terns Pharmaceuticals position peaked at $1.02M in Q2 2025.
  • 141 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.